These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8866 related articles for article (PubMed ID: 1394343)

  • 1. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.
    Morecki S; Revel-Vilk S; Nabet C; Pick M; Ackerstein A; Nagler A; Naparstek E; Ben Shahar M; Slavin S
    Cancer Immunol Immunother; 1992; 35(6):401-11. PubMed ID: 1394343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eosinophils activation in post-autologous bone marrow transplanted patients treated with subcutaneous interleukin-2 and interferon-alpha 2A immunotherapy.
    Fabian I; Kravtsov V; Elis A; Gurevitch O; Ackerstein A; Slavin S; Nagler A
    Leukemia; 1994 Aug; 8(8):1379-84. PubMed ID: 8057677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma.
    Castello G; Comella P; Manzo T; Napolitano M; Parziale AP; Galati MG; Daponte A; Casaretti R; Celentano E; Comella G
    Melanoma Res; 1993 Feb; 3(1):43-9. PubMed ID: 8471836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
    Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
    Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Murray C; Cochran K; Cameron C; Wang E; Schow PW; Daley JF; Ritz J
    Blood; 1992 Jan; 79(2):517-26. PubMed ID: 1730094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia.
    Baumgarten E; Schmid H; Pohl U; Brzoska J; Linderkamp C; Siegert W; Henze G
    Leukemia; 1994 May; 8(5):850-5. PubMed ID: 8182941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects.
    De Laurenzi A; Iudicone P; Zoli V; De Rosa L; Guglielmetti M; Pescarollo A; Papetti C; Pacilli L; Lapponi P; Petti N
    J Hematother; 1995 Apr; 4(2):113-20. PubMed ID: 7633841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected].
    Klingemann HG; Grigg AP; Wilkie-Boyd K; Barnett MJ; Eaves AC; Reece DE; Shepherd JD; Phillips GL
    Blood; 1991 Dec; 78(12):3306-11. PubMed ID: 1742491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
    Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
    Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a.
    Nagler A; Ackerstein A; Barak V; Slavin S
    J Hematother; 1994; 3(1):75-82. PubMed ID: 7922012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group.
    Queirolo P; Ponte M; Gipponi M; Cafiero F; Peressini A; Semino C; Pietra G; Lionetto R; Vecchio S; Ribizzi I; Melioli G; Sertoli MR
    Ann Surg Oncol; 1999; 6(3):272-8. PubMed ID: 10340886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants.
    Slavin S; Nagler A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S59-67. PubMed ID: 9457396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.
    Vey N; Viens P; Fossat C; Olive D; Sainty D; Baume D; Stoppa AM; Bouabdallah R; Brandely M; Gastaut JA; Maraninchi D; Blaise D
    Eur Cytokine Netw; 1997 Dec; 8(4):389-94. PubMed ID: 9459619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
    Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
    Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
    Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
    Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological changes in peripheral blood mononuclear cells of patients with metastatic renal cell carcinoma after low doses of subcutaneous immunotherapy with IFN-alpha-2b and IL-2.
    Moltó L; Carballido J; Manzano L; Martinez-Martin B; Esquivel F; Chafer J; Olivier C; Alvarez-Mon M
    J Immunother; 1999 May; 22(3):260-7. PubMed ID: 10335486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
    Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
    Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 444.